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ABSTRACT
Drug-induced hypersensitivity reactions have been explained by the hapten concept, according to which a
small chemical compound is too small to be recognized by the immune system. Only after covalently binding to
an endogenous protein the immune system reacts to this so called hapten-carrier complex, as the larger mole-
cule (protein) is modified, and thus immunogenic for B and T cells. Consequently, a B and T cell immune re-
sponse might develop to the drug with very heterogeneous clinical manifestations．
In recent years, however, evidence has become stronger that not all drugs need to bind covalently to the MHC-
peptide complex in order to trigger an immune response. Rather, some drugs may bind directly and reversibly
to immune receptors like the major histocompatibility complex (MHC) or the T cell receptor (TCR), thereby
stimulating the cells similar to a pharmacological activation of other receptors. This concept has been termed
pharmacological interaction with immune receptors the (p-i) concept. While the exact mechanism is still a mat-
ter of debate, non-covalent drug presentation clearly leads to the activation of drug-specific T cells as docu-
mented for various drugs ( lidocaine , sulfamethoxazole ( SMX ) , lamotrigine , carbamazepine , p-
phenylendiamine, etc.).In some patients with drug hypersensitivity, such a response may occur within hours
even upon the first exposure to the drug. Thus, the reaction to the drug may not be due to a classical, primary
response, but rather be mediated by stimulating existing, pre-activated, peptide-specific T cells that are cross
specific for the drug. In this way, certain drugs may circumvent the checkpoints for immune activation imposed
by the classical antigen processing and presentation mechanisms, which may help to explain the peculiar na-
ture of many drug hypersensitivity reactions．
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INTRODUCTION
Modern medicine is based on a thorough under-
standing of the pathophysiological basis of diseases.
Therapeutic interventions often rely on chemicals
(xenobiotics) which may enhance or block a certain
function of cells or proteins and may thus have a
beneficial effect. The confrontation with such xenobi-
otics is not novel for humans and animals, as plants
contain many chemicals. Some plants have even been
used for therapeutic purposes for many centuries in
the form of phytotherapy. However, the amount and
variety of drugs to which we are exposed has surely
changed in the last century , where thousands of
newly synthesized and pure drugs entered and con-
quered the market, as some proved to be very effi-
cient for various purposes．
One could argue that the human race is not well
prepared to handle this high amount of xenobiotics to
which we are exposed in modern life―as such an ar-
tificial intervention was not foreseen in evolution. In-
deed, adverse side effects to drugs are a common in-
cidence in the clinical practice . Most reactions are
caused by the pharmacological or toxicological activi-
ties of the drug and are generally predictable (type
A). However, non-predictable, idiosyncratic (type B)
reactions1,2 may occur as well , amounting to about
16% of all cases. Most of the type B reactions are con-
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Table 1 The p-i-concept: arguments pro and contra 
PRO
Clinical: 
Appearance at the first encounter with the drug
Positive skin tests with drugs gaining immunogenicity by me-
tabolism in the liver 
Hypersensitivity reactions to drugs without known 
metabolism7,8,24-28 
Immunological/pharmacological:
Glutaraldehyde-fixed APC can stil present drug7,8,25-27,39
Washing removes drug and prevents T cel activation25,39
Kinetics of TCR downregulation too fast to alow antigen 
processing26
Kinetics of Ca2+ mobilization too fast to alow antigen 
processing26
Inhibition of SMX-NO generation by glutathione increases 
drug presentation32-35
High incidence of unrestricted, drug-reactive clones36
Elevated frequency of aloreactive drug-reactive clones com-
pared to peptide-specific TCC37
Exchange or removal of MHCI-associated peptides does 
not afect drug presentation38
Kinetics of ERK phosphorylation too fast to alow antigen 
processing39
CONTRA
Clearly established for chemicaly reactive drugs10-12,16,17
No evidence for it in animal experiments55,56
Strong associations between several MHCI aleles and drug 
hypersensitivity57-64
Table 2 The p-i concept-Pharmacological Interaction with 
Immune Receptors
A chemicaly inert drug, unable to covalently bind to 
proteins, is stil able to fit to some of the many immune 
receptors (as it does to other proteins/receptors). This 
reversible drug-receptor interaction can under certain 
circumstances activate immune cels specific for pep-
tide antigens, which expand and cause inflammatory 
reactions of diferent types. Such a reaction would not 
need the generation of a primary immune response to 
the drug, albeit an expansion of drug-reactive cels 
may be required before symptoms appear.
sidered to be immune mediated (drug hypersensitiv-
ity reactions). A substantial proportion of these side
effects actually involves effector-cells of the immune
system and an inflammatory response (e.g. basophilic
and eosinophilic leukocytes, mast cells), but no spe-
cific immune reaction to the drug can be shown (non
allergic hypersensitivity or pseudo-allergic reac-
tions)．
In drug-induced hypersensitivity reactions a small
chemical compound can elicit a strong systemic im-
mune reaction. The subsequent reactions may cause
diseases mimicking other diseases and can also be
seen as “experimental models”, where the eliciting
agent and the amount, pharmacology and metabolism
of the eliciting drug is well known. In classical drug
hypersensitivity different immune mechanisms are
involved and can lead to many clinically distinct dis-
eases.3,4 Some reactions are of the immediate type
and clearly mediated by IgE-antibodies,5 others in-
volve IgG and immune complexes. The most preva-
lent reactions are , however , T-cell mediated reac-
tions 3: Patients with drug hypersensitivity harbor
drug specific T cells in their peripheral blood and also
in the affected tissues.6-8 The functions of these drug-
specific T cells seem to determine the clinical picture
of the disease.3,9
Of crucial importance is the way how T cells are
stimulated by drugs. During the last years, our group
has investigated this problem in detail and we have
reached some surprising conclusions. In particular,
we proposed a new model, termed pharmacological
interaction with immune receptors (p-i) concept. This
model could explain some peculiar features of drug
allergies and would have a major impact on predictive
tests．
THE HAPTEN AND PROHAPTEN CONCEPT
An immune reaction starts with the involvement of
the innate immune system. The antigen (bacteria, vi-
rus, etc.) stimulates the innate immune system via
e. g. Toll like receptors (TLR) on dendritic cells ,
thereby setting an initial alarm signal. The activated
dendritic cells function as antigen-presenting cells
(APC) as they take up and process complex and
larger antigens, which subsequently are presented as
peptides to T cells in a suitable environment, mainly
the lymph nodes. The ensuing immune response is
variable and efficient, as different antigens like sol-
uble or cell bound viral antigens elicit a distinct im-
mune response, capable to eliminate the infectious
agent．
Small low-molecular weight compounds (MW＜
1000D ) are thought to be too small to elicit such an
immune response per se. Nevertheless, small com-
pounds such as drugs or metal ions have been found
to be able to trigger an immune response . 1-3 The
hapten (and pro-hapten) model has been developed
and is currently the accepted explanation for these
observations: Chemically reactive, small compounds
(=haptens) bind to proteins or peptides and modify
them.10-12 Thus, these haptens have two features es-
sential for triggering an immune response:
a) they may stimulate the innate immune system by
covalently binding to cellular proteins, thereby trans-
mitting a danger signal, which results in stimulation
of cells of the innate immune system . 13,14 Or , as
shown for imiquimod, they may happen to bind to
TLR7 & 8 directly and thus stimulate dendritic cells.15
b) they may stimulate the specific immune system :
By forming hapten-carrier complexes they form neo-
antigens . The hapten-protein complexes are proc-
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Fig. 1　A comparison of diferent smal antigens stimulating T-cels via the hapten, a hapten-like and the p-i 
mechanism. Penicilin, nickel ions (black bal), and SMX serve as the respective examples. Strong, covalent bonds 
between the antigens and the MHC and the TCR are indicated by solid lines, while weaker, noncovalent interac-
tions are depicted as dashed lines. For haptens, the majority of the antigen-binding energy stems from the interac-
tion with the MHC-peptide complex via few but strong covalent bonds (hapten; note that certain haptens may be 
strongly associated not only with the MHC but the TCR as wel).65 Ni may interact either like a non-covalent 
hapten,17 or as depicted here,16 forming equaly strong, non-covalent interactions with both MHC and TCR (nickel), 
while at least some drugs would derive the majority of their binding energy from weak, non-covalent interactions 
with the TCR (p-i-concept). These diferent modes of interaction represent a continuum of possibilities, with the 
(pro)hapten mode on one extreme of the spectrum, the p-i-concept mode representing the other extreme, and the 
Ni mode as an intermediate possibility.
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essed and presented as hapten-modified peptides to T
cells, which can react with it.16-18 Modified proteins
can also be immunogenic for B-cells and thus elicit a
humoral immune response. These modification can
occur on soluble proteins, cell bound proteins or in
the MHC-peptide complexes themselves leading to
distinct immune responses．
Pro-haptens are per se not chemically reactive and
not able to form a covalent bond with a peptide: in or-
der to become chemically reactive, they first need to
be converted into a hapten by being metabolized into
a compound that is chemically reactive . 1,2,18,19 Me-
tabolism may occur in the liver, where it may not nec-
essarily induce an immune response, but actually tol-
erance.20 On the other hand, if a reactive compound
escapes the tolerogenic environment of the liver or if
the immune response to the compound is developed
in lymph nodes outside of the liver (like probably in
severe drug hypersensitivity syndromes) an accom-
panying hepatitis may occur.21
THE P-I CONCEPT
The hapten and prohapten concept elegantly circum-
vents the (presumed) blindness of the immune sys-
tem for low molecular weight compounds by postulat-
ing chemical reactivity and subsequent coupling to a
macromolecular carrier an absolute necessity. As a
consequence, drugs and other substances that are in-
capable of such conjugation with a carrier would not
be antigens and could not induce hypersensitivity re-
actions. However, there is clear clinical, immunologi-
cal and biochemical evidence to the contrary (Ta-
ble 1 and below).
CLINICAL DATA:
Some drugs appear to be able to stimulate an appar-
ently specific immune response to a drug at the first
encounter, before an immune response has had time
to evolve. Other reactions seem to occur in less than
three days. These time intervals seem too short to
mount a specific immune response.
Some drugs causing delayed hypersensitivity reac-
tions are not known to be metabolized to a chemically
reactive compound: e.g. contrast media can cause de-
layed, clearly T-cell mediated hypersensitivity reac-
tions in 1―2% of patients exposed to it, often at the
first encounter, but no metabolism occurs and no pro-
tein binding has been detected.22 Thus, the hapten
concept cannot explain allergic side effects to these
drugs．
Many chemically inert drugs , unable to form
hapten-carrier complexes in the skin, are neverthe-
less able to cause positive skin tests with lymphocyte
infiltration.22-24 It is difficult to imagine that a drug lo-
cally applied in an epicutaneous patch tests is trans-
ported to the liver, metabolized there and returned to
the skin to cause a local reaction there．
IMMUNOLOGICAL DATA:
The generation of drug specific T cell clones (TCC)
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Fig. 2 Comparison of hapten and p-i concept: note that hapten-like and non-hapten-like bindings have diferent re-
quirements for immune cel activation, and result in a primary triggering of either APC (hapten) or of T cels (which is 
supplemented by interactions with APC). 
Antigenicity of drugs: differences in immunogenicty and implications for preclinical testing
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Hapten (e.g. SMX-NO)
●　Chemical (hapten), covalent binding
●　Often processing and metabolism involved 
●　MHC-APC directed
●　Stable protein/peptide modification (covalent)
●　Very heterogeneous and often combined
 immune responses  (Ig, T-cells)
●　Structural (fitting into TCR), no covalent binding
●　No covalent binding
●　TCR-T cell directed
●　No processing/no metabolism
●　Only (?) T-cell reactions of different types
 (exanthema, DreSS, AGEP* etc.)
 *DreSS: Drug rash with eosinophilia and systemic symptoms; AGEP: Acute generalized exanthematous pustulosis
p-i concept (e.g. SMX)
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paved the way to a better analysis of drug―T cell
stimulations: Several observations argue against proc-
essing or covalent binding．
1) Only some T cells of a patient with drug hyper-
sensitivity react with the drug. Using TCC, many dif-
ferent, chemically inert drugs were found to be able
to stimulate T cells via the TCR in an MHC-
dependent way , in particular lamotrigine , 7 car-
bamazepine,8 sulfamethoxazole (SMX),25,26 mepiva-
caine 27 and lidocaine , 24,27 p-phenylendiamine , 28
ciproxin or moxifloxacin , and radio contrast media
(RCM).29,30
2) Specific TCC reacted even if the APC were fixed
by glutaraldehyde, excluding that either processing
or intracellular metabolism is involved.7,8,25-27
3) Unlike typical haptens, certain drugs do not re-
quire covalent binding. Upon pulsing of APC (incuba-
tion of APC with the drug for 1h followed by two
washing steps, which remove the drug) , no T cell
stimulation was observed for lidocaine, lamotrigine,
carbamazepine, ciproxin and SMX.7,8,26,31 SMX has
been characterized particularly well , as its reactive
metabolite SMX-nitroso (SMX-NO), acting as a typi-
cal hapten, was available for comparison.32,33 In con-
trast , the hapten SMX-NO , capable of covalently
modifying the MHC-peptide complex, was still able to
stimulate hapten-reactive T cells.25
4) For a number of drugs, the kinetics of T cell acti-
vation are simply much too fast for any involvement
of antigen processing. In the presence of APC, lido-
caine and SMX activate T cells quasi immediately as
revealed by a rapid and sustained intracellular Ca2+
increase.26 It is impossible to reconcile this timing
with an intermediate metabolism and processing
step, which needs 60 min or longer to occur. Also,
the kinetics of TCR down-regulation on drug reactive
TCC after encountering the inert drug are similar to
the recognition of pre-processed, immunogenic pep-
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Table 3 Drugs documented to stimulate T-cels via non-covalent binding and coresponding clinical symptoms
SymptomsDrugs
・Maculopapular exanthema25
 Toxic epidermal necrolysis66
・Sulfamethoxazole (SMX)
・Contact dermatitis & ery thema exsudativum multiforme24・Lidocaine/Mepivacaine
・Acute generalized exanthematous pustulosis67・Celecoxib
・Drug rash with eosinophilia and systemic symptoms8・Carbamazepine
 ・ Drug rash with eosinophilia and systemic symptoms7・Lamotrigine
・Maculopapular exanthema31・Ciproxin
・Contact dermatitis28・P-phenylendiamine
tides (occurring within the first 30 min), and clearly
differ from the recognition of proteins , which re-
quires several hours.26
5) Hypersensitivity to the drug SMX was thought
to be a consequence of bioactivation to the hydrox-
ylamine metabolite (SMX-NHOH) and further oxida-
tion to the ultimate , reactive metabolite SMX-NO .
The antioxidant glutathione is known to protect cells
from reactive metabolites like SMX-NO by conjuga-
tion and subsequent dissociation to SMX-NHOH
andor SMX.33 In contrast to this concept, only a mi-
nority of TCC derived from SMX-allergic patients re-
acted with SMX-NO.34 The use of inhibitors of me-
tabolism further supported the role of SMX and not of
SMX-NO: Addition of glutathione to peripheral blood
mononuclear cells enhanced rather than reduced the
proliferation to SMX-metabolites , 35 presumably by
transforming SMX-NO back to the “original” antigen,
SMX. The response of SMX-NO-specific TCC was ab-
rogated when glutathione was present during the co-
valent modification of antigen presenting cells (APC).
Collectively, these experiments support the concept
that T cells in allergic individuals recognize the non-
covalently bound parent drug SMX rather than APC
covalently modified by SMX-NO.34,35
6) Last but not least, drug specific TCC show some
peculiar features, reminiscent of superantigen stimu-
lations, but not seen with classical peptide antigens:
Many drug-specific TCC were found to be MHC-
unrestricted,36 and the frequency of alloreactive TCC
is much higher among drug- than peptide-specific
TCC from the same donor.37 The MHC-bound pep-
tide seems to be irrelevant for SMX-specific T cell ac-
tivation.38 Lastly, drugs simultaneously elicit a CD4
and CD8 T cell response to the same compound．
T-CELL RECEPTOR TRANSFECTED HYBRI-
DOMA CELLS:
To further study these unusual characteristics of
drug-T-cell interactions we recently developed drug-
specific TCR transfectants , which incontrovertibly
demonstrated that T-cell activation by drugs is TCR-
dependent39: Two SMX-specific human TCR were in-
troduced into the mouse T cell hybridoma cell line 54
ζ 17 (O . Acuto , Paris , France ) according to the
method described by Vollmer et al.. 40 These trans-
fectants expressed drug-specific TCR on the cell-
surface, and could be stimulated in a specific way in
the presence of antigen presenting cells (APC), re-
sulting in IL-2 secretion. These TCR-transfected hy-
bridoma cells behaved like drug-specific TCC, as the
drug could be washed away (contrary to haptens co-
valently bound to carrier molecules), the presence of
APC (MHC) was required for IL-2 production, and
fixed APC were still able to present the drug. Simi-
larly, the kinetics of TCR activation were too fast to
involve antigen processing , as antigen-dependent
ERK phosphorylation was detected within one minute
of SMX exposure．
Since the hapten concept does not suffice any more
to account for all the above observations we have re-
cently proposed a third model, which is meant to sup-
plement the haptenpro-hapten concept . 41 Termed
the p-i concept , which stands for “direct pharma-
cological interaction of drugs with immune recep-
tors” ,41 it states that certain drugs would bind spe-
cifically and reversibly to some of the highly variable
antigen specific receptors in a direct way, instead of
covalently modifying the MHC-peptide complex ,
which are the two feasible “partners” to accommo-
date allergy-inducing drugs (Table 2) . Such a drug-
TCR interaction would be metabolism- and
processing-independent and in fact mimic drug inter-
actions with other , non-immunological receptors .
While the MHC-peptide complex would not contrib-
ute (much) to the binding energy, it would still be
necessary a) for full T cell activation and b) to direct
the cytotoxic immune response at a target cell. This
model has been elucidated for TCR, but it is possible
that also BCR on B-cells are activated via a similar
mechanism．
Why do we think the TCR to be the more likely
candidate for drug binding than the MHC, which is
the “ traditional ” antigen-binding receptor ? Such a
mechanism seems feasible and at least one precedent
has already been reported: Divalent Nickel ions (Ni)
do not bind to proteins covalently but rather by form-
ing reversible coordination complexes . 42 Weltzien
and coworkers identified and characterized a HLA-
DR-promiscuous, Ni-specific TCR where Ni interacts
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simultaneously with the MHC and TCR by making
contacts with a conserved His81 in the HLA-DR α-
chain as well as Tyr29 and Tyr94 in CDR1α of the
TCR. Thus, Ni forms a bridge between both recep-
tors―much like a superantigen even though requir-
ing idiotypic residues in the TCR.16 Ni has six coordi-
nation sites, of which only three are known for this
complex at present. Nevertheless, a substantial part
of its binding energy will be derived by the (at least)
two contacts with the TCR of this complex. In fact, Ni
binding may represent a “compromise” between how
a typical hapten and a small antigen incapable of cova-
lent binding may interact with the MHC and the TCR
( see Figure 1 and legends for a detailed explana-
tion)．
It has been known for many years that drugs can
activate receptors that have peptides or proteins as
endogenous receptors , the classical example being
the opiate alkaloids. For these as well as many other
serpentine receptors , a myriad of compounds are
known to bind to these receptors and evoke many
pharmacologically different responses . More re-
cently, non-peptide agonists have also been found for
tyrosine kinases as well as growth factor and cytokine
receptors.43 αβ TCR are peptide receptors. However,
apart from a hydrophobic cleft between the CDR3α
and CDR3β regions, the TCR does not feature a “suit-
able” binding pocket or groove for small molecular
weight compounds such as other peptide receptors.
Still , one should certainly not exclude categorically
that some drugs may bind to a particular TCR, espe-
cially given the huge TCR repertoire and the high
level of cross-reactivity just from a probabilistic point
of view alone.44 It is also worthwhile remembering
that the overwhelming majority of low molecular
weight, “drug-like” compounds known to bind to dif-
fering receptor classes act as antagonists. In analogy
to these findings, it seems not unlikely that at least
some drugs may not only activate but also block their
(drug-specific) TCR．
THE P-I CONCEPT : BYPASSING THE IN-
NATE IMMUNE SYSTEM BY VIRTUE OF
CROSSREACTIVITY WITH PEPTIDE ANTI-
GENS
The p-i concept has major implications for our inter-
pretation of drug induced immune mediated side ef-
fects: It actually puts some drug induced hypersensi-
tivity reactions outside the realms of a normal im-
mune response (Fig. 2).45 This reasoning could ex-
plain some peculiar clinical findings , namely that
drug-induced, T cell-mediated skin reactions can oc-
cur already within a few hours after administration
andor without previous exposure to the drug, as e.g.
documented for RCM.29,30 The kinetics of such a re-
action are much too fast to be explained by the induc-
tion of a classical , primary response , which is
mounted in the course of several days only . More-
over, how do RCM or other inert drugs stimulate the
innate immune system, a step normally required to
induce an immune response ? Such features have
been described for certain haptens causing contact
dermatitis, but are not described for inert drugs.13,14
To explain these phenomena we proposed that
such drugs are bypassing the innate immune system
as they stimulate memory T cells (with a peptide
specificity).46,47 Such memory T cells have a lower
threshold of reactivity compared to naïve T cells ,
which might be decreased even further if a general-
ized immune reaction with its abundance of cytokines
is occurring. A secondary, memory response by the
immune system is generally much faster and can lead
to an immune reaction within the time frame ob-
served for some adverse drug reactions. Moreover,
these features would explain the higher incidence of
drug hypersensitivity reactions during such infec-
tions or autoimmune diseases. It implies that drug
hypersensitivity reactions are actually due to cross-
reactivity of peptide specific memory T cells, which
“just happen” to react with some drugs as well. In line
with this notion is the observation that the vast major-
ity of drug-specific TCC have been found to bear αβ
TCR, which usually recognize peptides , and that a
general stimulation of T cells as in HIV or EBV, CMV
infection48 or certain exacerbations of autoimmune
diseases49 is an important risk factor for drug hyper-
sensitivity. On the other hand, recent data suggest
that a drug-induced T cell activation leads to a reacti-
vation of dormant herpes viruses, and that the subse-
quent symptoms are largely related to reactivated
herpes virus infections.50,51 The normal incidence of
SMX allergy in normals is ca. 2―4%, but during HIV
infection it might go up to ca. 50%, while amoxicillin
hypersensitivity increases from 4―5% in normals to >
90% during an acute EBV infection (infectious mono-
nucleosis). Such immune reactions go along with the
expansion of a polyclonal CD8+ T cell response, and
such T cells are also found in the circulation of pa-
tients with maculopapular and bullous exanthema.52
Even more, it seems likely that drug-specific cells ex-
ist even in individuals that are not hypersensitive: in
an in vitro study, several blood donors who had never
been exposed to SMX nevertheless harbored SMX-
and SMX-NO-specific cells in their T cell repertoire.53
Preclinical testing for drug hypersensitivity is of
notoriously bad reliability54: One explanation might
be that the attempts to perform preclinical tests rely
on the hapten-prohapten concept only, but ignore the
p-i concept. As shown in Figure 2, the p-i and hapten
concepts have quite distinct features and would re-
quire different approaches. Tests relying on chemical
reactivity and aimed to detect hapten formation and
the induction of a classical immune response would
necessarily miss drugs that elicit hypersensitivity re-
actions via non-covalent binding to the TCR. Of note
and as shown in Table 3, this may be the case for a
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substantial number of drugs.
ARGUMENTS AGAINST THE P-I CONCEPT:
The p-i concept was not conceived to oppose the hap-
ten or pro-hapten concept, but to complement it. Cer-
tain drugs like penicillins clearly do cause hypersen-
sitivity reactions due to hapten-carrier formation. Oth-
ers, like quinolones and sulfanilamides, may cause
hypersensitivity by the hapten and p-i mechanisms
simultaneously.4,31,34 Thus, if the hapten concept is
well proven for a certain drug like p-phenylendiamine
or sulfamethoxazole,26,28 it cannot be ruled out that
the p-i concept may not also play some role．
The p-i concept is contradicting many rules well es-
tablished in immunology, which makes it at first sight
a hypothesis “hard to digest” . However, the findings
in drug allergy do also contradict many established
rules,45 and exactly the fact that the p-i concept is not
postulating a primary immune response to a drug
may explain many of these puzzling findings. Drug
hypersensitivity generated according to the p-i con-
cept does not require the involvement of the innate
immune system to trigger immunity, as this form of
drug hypersensitivity is not due to a newly generated
immune response to the drug but is the consequence
of cross-reactivity . Animal experiments aimed to
prove or disprove the p-i concept by immunizing ani-
mals with the inert drug will necessary fail―as inert
drugs do not stimulate an immune response under
normal conditions.55,56 In fact, it might be impossible
to prove the p-i concept by the usual immunological
tests ; rather , it will be corroborated by a pharma-
cological characterization of the TCR-drug interac-
tions．
The strongest argument against the p-i concept
and our idea that drugs primarily activate the TCR
comes from new immunogenetic data. Already early
on, the idiosyncratic nature of hypersensitivity reac-
tions has prompted an intensive search for genetic
factors explaining their occurrence in a small subset
of treated persons ( reviewed in) . 57 In accordance
with the (pro) hapten concept, the major emphasis
was put on pharmacogenetic factors such as an al-
tered metabolism, as the generation of a more reac-
tive intermediate able to modify autologous proteins
would have been the most stringent explanation for
the occurrence of immunological side effects. How-
ever, associations of hypersensitivities with particular
pharmacological genotypes remained often tenuous
and even controversial,58 such as the slow acetylator
phenotype reported to enhance the occurrence of
side effects to SMX,59 and the moderate association
of certain TNF-α promoter polymorphisms with car-
bamazepine hypersensitivity.60
More recent studies focusing on immunological
rather than metabolic factors have now revealed sur-
prisingly clear associations of certain drug hypersen-
sitivity reactions with HLA-class I alleles. In approxi-
mately 5% of treated patients, abacavir causes a se-
vere hypersensitivity reaction affecting multiple or-
gans. The majority of these patients carried the HLA-
B*5701 allele. This association was strongest in Cau-
casians , 61 and the particular allele was present in
94.4% of patients but only 1.7% of controls.62 Possibly
even more striking is the association of car-
bamazepine treatment with the appearance of
Stevens-Johnson syndrome in Han-Chinese carrying
the HLA-B 1502 allele,63 which is stronger than any
other described so far for any HLA marker with a dis-
ease. In a another case-control association study, the
same authors identified HLA-B*5801 as an important
genetic risk factor for severe allopurinol-induced cu-
taneous adverse reactions such as Stevens-Johnson
syndrome and toxic epidermal necrolysis.64
It is clear that such strong associations with HLA-
alleles support an important role for HLA molecules
in drug hypersensitivity, and they certainly seem to
favor the hapten concept at least for these drugs .
However , albeit the association with HLA-alleles is
very strong, there are some open questions: Many
patients with HLA-B*5801 are exposed to allopurinol
yet they do not develop hypersensitivity . 64 Cauca-
sians do not show the association of HLA-B*5701 and
carbamazepine hypersensitivity,61,62 but most TCC to
carbamazepine generated from Caucasians reacted
with the parent compound―and it is therefore possi-
ble that the particular Chinese population reacted to a
hapten of carbamazepine. Also and as reported by the
authors of these studies, other factors located in this
region of chromosome 6 may be important as well (e.
g. hsp 70 and other genes). Last but not least, not the
HLA complex but the TCR as its counterpart might
be crucial for the reaction, as the positive and nega-
tive selection of T cells in the thymus is co-
determined by the autologous HLA-molecules and
peptides that can be presented at all, thus influencing
the TCR repertoire of the individual patient．
CONCLUSIONS
A series of clinical and laboratory investigations con-
tradict the hapten model and suggest that the hapten
model as the sole molecular explanation for drug-
induced hypersensitivity may not be sufficient. Other
possibilities should be considered and we recently
proposed the p-i concept , which supplements the
hapten-concept. In this concept certain drugs are con-
sidered to be able to activate T cells in a direct way by
drug binding to T-cell receptors and subsequent cell
activation. This mechanism would explain many of
the peculiar findings in drug hypersensitivity , and
would open new possibilities for immuno-
pharmacology, as this drug binding may be stimula-
tory or inhibitory．
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